A subcutaneous version of Daiichi Sankyo’s AstraZeneca-partnered blockbuster antibody-drug conjugate (ADC) Enhertu could be ...
Fierce Pharma Asia—AstraZeneca's China fallout; Pfizer's $1B plan in China; Incyte-Sun JAK dispute
AstraZeneca's China president has been detained by Chinese authorities amid investigation into illegal importation and ...
J&J’s filing is based on results from the phase 3 AQUILA trial. Among 390 patients with high-risk smoldering multiple myeloma ...
Investment fund Oaktree calls for board shakeup at Indivior, accusing company of 'value destruction'
With Indivior’s stock price in freefall over the past year, one of the company’s top investors is taking leadership to task, ...
Of the top 20, Novo and Lilly were among only six companies that witnessed declines in their market value in the third ...
An FDA expansion of Sarepta Therapeutics’ Duchenne muscular dystrophy (DMD) Elevidys has sparked a new surge in sales for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback